Alzheimer's disease (AD) is recognized to have a long presymptomatic period, during which
there is progressive accumulation of molecular pathology, followed by inexorable neuronal …

Alzheimer's disease (AD) is increasingly prevalent worldwide, and disease‐modifying
treatments may soon be at hand; hence, now, more than ever, there is a need to develop …

Objectives: To investigate whether serum neurofilament light (NfL) concentration is
increased in familial Alzheimer disease (FAD), both pre and post symptom onset, and …

Background The causes of phenotypic heterogeneity in familial Alzheimer's disease with
autosomal dominant inheritance are not well understood. We aimed to characterise clinical …

Blood biomarkers have great potential to advance clinical care and accelerate trials in
Alzheimer's disease (AD). Plasma phospho-tau181 (p-tau181) is a promising blood …

Background Tests sensitive to presymptomatic changes in Alzheimer's disease could be
valuable for clinical trials. Accelerated long-term forgetting—during which memory …

Background Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a
diagnosis of Alzheimer's disease (AD). Their clinical utility for differentiating AD from non-AD …

Importance This study assesses factors associated with the most common adverse event
following lumbar puncture. Objective To identify factors associated with the risk, onset, and …

Background Understanding the earliest manifestations of Alzheimer's disease (AD) is key to
realising disease-modifying treatments. Advances in neuroimaging and fluid biomarkers …

Background To investigate how serum neurofilament light (NfL) concentration changes
through the course of disease in familial Alzheimer's disease (FAD) and to assess when NfL …